Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis

This article was originally published in The Pink Sheet Daily

Executive Summary

The restructuring leaves oncology and IDEC behind and reemphasizes the "Biogen" in Biogen Idec.

You may also be interested in...



Biogen Begins Its Oncology Sell-Off, Parting With Two Kinase Inhibitors

New CEO George Scangos pledged in November to return Biogen Idec to its neurology and immunology roots. This is the first divestment deal under the new regime.

Biogen Begins Its Oncology Sell-Off, Parting With Two Kinase Inhibitors

New CEO George Scangos pledged in November to return Biogen Idec to its neurology and immunology roots. This is the first divestment deal under the new regime.

Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?

Since his arrival as CEO nearly seven months ago, Biogen Idec Inc.’s George Scangos has been exerting his influence in ways both big and small. None may have more lasting impact than his recruitment of two top industry executives, Steven Holtzman and Doug Williams, to take the reins respectively as Biogen’s executive VP of corporate development and executive VP of R&D.

Related Content

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel